Open access · CC-BY
via OpenAlex
Glycemic and Extraglycemic Effects of Metformin in Patients with Diabetes
IntechOpen eBooks · 2023
Abstract
For several decades, metformin has been the mainstay of treatment of type 2 diabetes (T2D), not only due to its remarkable efficacy in both monotherapy and combination therapy regimens, but also due to its favorable safety profile, weight neutrality, and low cost. Other advantages have been reported, including improvements in lipid profile and inflammatory markers and reports of cardioprotective effects, albeit with scant evidence. The modification of the cellular energy metabolism is the core of metformin’s mode of action. Metformin works to lower serum glucose concentration by inhibiting hepatic gluconeogenesis and countering the action of glucagon. Secondarily, it enhances glucose uptake in peripheral tissues, predominantly in the muscles. Long-term and widespread use of metformin has shed light on its other potential uses mediated by its effects on deranged metabolic pathways. Moreover, metformin is gaining research interest by demonstrating its potential in the treatment of multiple disorders other than diabetes and has been proven to have anti-cancer, immunoregulatory, and anti-aging properties. As a result, metformin is currently being researched as a potential treatment option for various diseases.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.5772/intechopen.109357
- Canonical
- link ↗
- Fetched
- 2026-10-08 MST
Cite this
APA
Rahelić, D., & Šakić, Z. (2023). Glycemic and Extraglycemic Effects of Metformin in Patients with Diabetes. <em>IntechOpen eBooks</em>. https://doi.org/10.5772/intechopen.109357
Vancouver
Rahelić D, Šakić Z. Glycemic and Extraglycemic Effects of Metformin in Patients with Diabetes. IntechOpen eBooks. 2023. doi:10.5772/intechopen.109357.
BibTeX
@article{dario2023Glycem,
title = {Glycemic and Extraglycemic Effects of Metformin in Patients with Diabetes},
author = {Dario Rahelić and Zrinka Šakić},
journal = {IntechOpen eBooks},
year = {2023},
doi = {10.5772/intechopen.109357},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Innovation in Aging 2024
Open access · CC-BY
METFORMIN AS A POTENTIAL PHARMACOLOGIC INTERVENTION TO IMPROVE HEALTHSPAN
Journal of Education Health and Sport 2025
Open access · CC-BY
Metformin - An Antidiabetic Drug With Anti-aging, Cardioprotective And Potential Anti-cancer Properties
The Science Journal of the Lander College of Arts and Sciences 2021
Preprint · OA
Rapamycin and Metformin in Treating COVID-19
Diabetes Obesity and Metabolism 2024
Open access · CC-BY
Metformin beyond type 2 diabetes: Emerging and potential new indications
Endokrynologia Polska 2017
Open access · CC-BY
Metformin — a new old drug
IntechOpen eBooks 2020
Open access · CC-BY